/ Print /

Drug costs

Payers to pharma: Here’s what we’re missing in hep C drugsA Precision for Value survey highlights what can be done in order to encourage payers to ease coverage policies for these drugs in the next wave of HCV treatment.
Top challenges in cancer careCancer drug costs remain the most critical challenge in care, among other things.
How state-mandated formularies impact costsResearch by Express Scripts presented at the AMCP examines costs among Medicaid members in the Florida plan to members in a similar Medicaid plan without a state-mandated formulary.
Copay assistance programs: Managed care pros and consDo copay assistance program offer a long-term solution for patients? Experts weigh in.
Three ways to rein in drug costs regardless of who becomes presidentIt’s time for stakeholders to cooperate in order to limit the wasted spending on prescription medications and chart a path to collectively improving value derivation.
Drug pipeline developments: Alopecia areata and atopic dermatitisPromising treatments are coming for alopecia areata and atopic dermatitis, but they will come at a high cost.
Nearly half of BCBS members discontinue this RA drug after 1 yearAnalysis from Prime shows that improvements in persistency, adherence is key in RA treatments.
Five specialty pharmaceutical trends to watchApprovals of specialty pharmaceuticals have far outpaced traditional drugs, and that trend will continue. But that’s not the only specialty medication trend that healthcare executives should have on their radar.
Study: New cholesterol drugs cost 356 times more than genericsA report from the Alliance of Community Health Plans can help get a better sense of how well drugs help patients compared to other treatment options.
How the presidential candidates plan to rein in pharma costs
How the presidential candidates plan to rein in pharma costsFind out where each presidential candidate stands on key issues related to pharmaceutical costs.